6 assets in CNS Demyelinating Autoimmune Disease

Therapeutic assets addressing CNS Demyelinating Autoimmune Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide CNS Demyelinating Autoimmune Disease	Indapta Therapeutics, INC.	P1	CC (43)
Fludarabine CNS Demyelinating Autoimmune Disease	Indapta Therapeutics, INC.	P1	CC (43)
Idp-023 CNS Demyelinating Autoimmune Disease	Indapta Therapeutics, INC.	P1	CC (43)
Mesna CNS Demyelinating Autoimmune Disease	Indapta Therapeutics, INC.	P1	CC (43)
Ocrelizumab CNS Demyelinating Autoimmune Disease	Indapta Therapeutics, INC.	P1	CC (43)
Natalizumab CNS Demyelinating Autoimmune Disease	Queen Mary University of London	P2	NR ()